Joseph Marzano
Psychiatry · Sacramento, CANPI 1942259718
Payments from drug & device makers
Across 238 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$774
- Otsuka America Pharmaceutical, Inc.$738
- Neurocrine Biosciences, Inc.$481
- Teva Pharmaceuticals USA, Inc.$445
- Indivior Inc.$388
- plus $814 from 8 others
What the payments were for
- Food & beverage$4,63497%
- Education$1623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,155 |
| Johnson & Johnson | 24 | $774 |
| Otsuka America Pharmaceutical, Inc. | 55 | $738 |
| Neurocrine Biosciences, Inc. | 26 | $481 |
| Teva Pharmaceuticals USA, Inc. | 18 | $445 |
| Indivior Inc. | 21 | $388 |
| Alkermes, Inc. | 12 | $274 |
| Lundbeck LLC | 9 | $177 |
| Vanda Pharmaceuticals Inc. | 5 | $121 |
| AbbVie | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$238
- Austedo XR$112
- CAPLYTA$104
How this compares
$4,795 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 48 | $130,109 |
| Invega SustennaPaliperidone Palmitate | 39 | $129,917 |
| VraylarCariprazine Hcl | 16 | $25,903 |
| Lurasidone Hcl | 21 | $3,202 |
| Paliperidone ErPaliperidone | 25 | $2,578 |
| Clozapine | 24 | $1,429 |
| Aripiprazole | 57 | $1,240 |
| Quetiapine Fumarate | 54 | $1,094 |
| Olanzapine | 49 | $974 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $892 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $813 |
| Hydroxyzine Hcl | 57 | $731 |
| Gabapentin | 61 | $667 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $577 |
| Bupropion XlBupropion Hcl | 35 | $503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $738 | $130,10948 claims |
| Johnson & JohnsonInvega Sustenna | $774 | $129,91739 claims |
| AbbVieVraylar | $74 | $25,90316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Sacramento
- Susan SmigaSacramento$1.7M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.